Related Experiment Video
Updated: Aug 26, 2026

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
Published on: November 26, 2015
Vestibulotoxicity and ototoxicity of gentamicin in newborns at risk
1Beratungsstelle für Hoerbehinderte, Bezirksamt Neukoelln von Berlin, Germany. GottfriedAust@t-online.de
Insights
Gentamicin treatment in newborns shows a low risk of hearing or vestibular issues. This antibiotic is less ototoxic in neonates compared to older individuals when used therapeutically.
Area of Science:
- Neonatology
- Ototoxicity Research
- Pediatric Audiology
Background:
- Gentamicin is a critical antibiotic for neonatal infections but carries ototoxic risks.
- Previous studies suggest higher ototoxicity in adults and older children.
Purpose of the Study:
- To evaluate the ototoxic and vestibulotoxic effects of gentamicin in newborns.
- To compare the safety profile of gentamicin in neonates versus older populations.
Main Methods:
- Study 1: Retrospective analysis of hearing disorders in 8,333 children, identifying 134 with prior gentamicin exposure.
- Study 2: Comparative analysis of vestibular function in 30 gentamicin-treated newborns and 30 controls.
Main Results:
- Only 6.0% of newborns treated with gentamicin showed sensorineural hearing impairment, all with other risk factors.
- No significant differences in vestibular function (spontaneous eye movements, nystagmus parameters) were found between gentamicin-exposed newborns and controls.
Conclusions:
- Therapeutic doses of gentamicin demonstrate a lower ototoxic and vestibulotoxic potential in newborns compared to older age groups.
- Gentamicin can be considered relatively safe for neonatal use concerning hearing and vestibular function when administered under controlled therapeutic conditions.
Abstract:
Gentamicin is a potentially ototoxic drug routinely used for treatment of life-threatening infectious diseases in neonatology. In study 1, of 8,333 children examined for hearing disorders, 134 (1.6%) had received previous treatment with gentamicin. Only eight (6.0%) suffered from various extents of sensorineural hearing impairment, and all eight had a history of other risk factors of hearing loss (e.g., perinatal asphyxia, acidosis, icterus gravis, or meningitis). In study 2, 30 children (mean age, 13.2 months) with normal hearing had received gentamicin during the newborn phase, and 30 healthy children of similar age without previous gentamicin treatment were examined for vestibular function. Neither in the number of spontaneous eye movements nor in the means of the nystagmus parameters of the rotatory test did the data show any significant difference between the groups. The results indicate that gentamicin in controlled therapeutic doses has a less ototoxic and vestibulotoxic effect in newborns than it does in older children or in adults.
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Teratogenicity
Drug Dosing: Infants and Children

